vs

Side-by-side financial comparison of AMREP CORP. (AXR) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $14.6M, roughly 1.9× AMREP CORP.). AMREP CORP. runs the higher net margin — 21.6% vs -71.0%, a 92.6% gap on every dollar of revenue. On growth, AMREP CORP. posted the faster year-over-year revenue change (93.8% vs 72.6%). AMREP CORP. produced more free cash flow last quarter ($5.4M vs $-31.8M).

AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

AXR vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.9× larger
ZYME
$27.6M
$14.6M
AXR
Growing faster (revenue YoY)
AXR
AXR
+21.2% gap
AXR
93.8%
72.6%
ZYME
Higher net margin
AXR
AXR
92.6% more per $
AXR
21.6%
-71.0%
ZYME
More free cash flow
AXR
AXR
$37.2M more FCF
AXR
$5.4M
$-31.8M
ZYME

Income Statement — Q3 FY2026 vs Q3 FY2025

Metric
AXR
AXR
ZYME
ZYME
Revenue
$14.6M
$27.6M
Net Profit
$3.1M
$-19.6M
Gross Margin
Operating Margin
20.6%
-80.1%
Net Margin
21.6%
-71.0%
Revenue YoY
93.8%
72.6%
Net Profit YoY
338.9%
34.3%
EPS (diluted)
$0.58
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXR
AXR
ZYME
ZYME
Q1 26
$14.6M
Q4 25
$9.4M
Q3 25
$17.9M
$27.6M
Q2 25
$11.2M
$48.7M
Q1 25
$7.5M
$27.1M
Q4 24
$11.9M
$31.0M
Q3 24
$19.1M
$16.0M
Q2 24
$19.5M
$19.2M
Net Profit
AXR
AXR
ZYME
ZYME
Q1 26
$3.1M
Q4 25
$1.2M
Q3 25
$4.7M
$-19.6M
Q2 25
$3.9M
$2.3M
Q1 25
$717.0K
$-22.6M
Q4 24
$4.0M
$-23.5M
Q3 24
$4.1M
$-29.9M
Q2 24
$4.1M
$-37.7M
Operating Margin
AXR
AXR
ZYME
ZYME
Q1 26
20.6%
Q4 25
11.9%
Q3 25
34.4%
-80.1%
Q2 25
31.7%
-1.4%
Q1 25
5.7%
-94.5%
Q4 24
26.4%
-71.6%
Q3 24
26.1%
-213.8%
Q2 24
23.9%
-222.9%
Net Margin
AXR
AXR
ZYME
ZYME
Q1 26
21.6%
Q4 25
12.8%
Q3 25
26.3%
-71.0%
Q2 25
34.8%
4.8%
Q1 25
9.5%
-83.5%
Q4 24
33.9%
-75.8%
Q3 24
21.3%
-186.6%
Q2 24
21.2%
-195.8%
EPS (diluted)
AXR
AXR
ZYME
ZYME
Q1 26
$0.58
Q4 25
$0.22
Q3 25
$0.87
$-0.26
Q2 25
$0.73
$0.03
Q1 25
$0.13
$-0.30
Q4 24
$0.75
$-0.32
Q3 24
$0.76
$-0.39
Q2 24
$0.77
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXR
AXR
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$50.0M
$64.8M
Total DebtLower is stronger
$21.0K
Stockholders' EquityBook value
$139.4M
$320.1M
Total Assets
$143.9M
$397.3M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXR
AXR
ZYME
ZYME
Q1 26
$50.0M
Q4 25
$44.6M
Q3 25
$48.9M
$64.8M
Q2 25
$39.5M
$98.3M
Q1 25
$36.9M
$76.2M
Q4 24
$40.1M
$66.1M
Q3 24
$40.4M
$122.4M
Q2 24
$29.7M
$71.0M
Total Debt
AXR
AXR
ZYME
ZYME
Q1 26
$21.0K
Q4 25
$23.0K
Q3 25
$25.0K
Q2 25
$26.0K
Q1 25
$29.0K
Q4 24
$32.0K
Q3 24
$34.0K
Q2 24
$35.0K
Stockholders' Equity
AXR
AXR
ZYME
ZYME
Q1 26
$139.4M
Q4 25
$136.0M
Q3 25
$134.7M
$320.1M
Q2 25
$130.0M
$334.5M
Q1 25
$126.0M
$325.0M
Q4 24
$125.1M
$338.8M
Q3 24
$122.2M
$367.0M
Q2 24
$118.0M
$406.2M
Total Assets
AXR
AXR
ZYME
ZYME
Q1 26
$143.9M
Q4 25
$140.1M
Q3 25
$140.7M
$397.3M
Q2 25
$133.8M
$408.4M
Q1 25
$128.9M
$425.5M
Q4 24
$129.1M
$463.1M
Q3 24
$127.0M
$487.2M
Q2 24
$122.8M
$515.6M
Debt / Equity
AXR
AXR
ZYME
ZYME
Q1 26
0.00×
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXR
AXR
ZYME
ZYME
Operating Cash FlowLast quarter
$5.4M
$-31.4M
Free Cash FlowOCF − Capex
$5.4M
$-31.8M
FCF MarginFCF / Revenue
37.0%
-115.2%
Capex IntensityCapex / Revenue
0.1%
1.5%
Cash ConversionOCF / Net Profit
1.72×
TTM Free Cash FlowTrailing 4 quarters
$20.2M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXR
AXR
ZYME
ZYME
Q1 26
$5.4M
Q4 25
$-4.3M
Q3 25
$9.5M
$-31.4M
Q2 25
$10.2M
$12.1M
Q1 25
$-3.2M
$-3.4M
Q4 24
$-182.0K
$-41.5M
Q3 24
$10.7M
$-5.9M
Q2 24
$10.7M
$-25.0M
Free Cash Flow
AXR
AXR
ZYME
ZYME
Q1 26
$5.4M
Q4 25
$-4.3M
Q3 25
$9.5M
$-31.8M
Q2 25
$9.7M
$11.6M
Q1 25
$-3.3M
$-3.4M
Q4 24
$-268.0K
$-41.8M
Q3 24
$10.7M
$-6.8M
Q2 24
$10.3M
$-25.6M
FCF Margin
AXR
AXR
ZYME
ZYME
Q1 26
37.0%
Q4 25
-45.9%
Q3 25
53.2%
-115.2%
Q2 25
86.4%
23.7%
Q1 25
-43.4%
-12.6%
Q4 24
-2.3%
-134.8%
Q3 24
55.8%
-42.4%
Q2 24
52.5%
-133.0%
Capex Intensity
AXR
AXR
ZYME
ZYME
Q1 26
0.1%
Q4 25
0.6%
Q3 25
0.1%
1.5%
Q2 25
5.2%
1.1%
Q1 25
0.3%
0.1%
Q4 24
0.7%
1.0%
Q3 24
0.2%
5.6%
Q2 24
2.3%
3.1%
Cash Conversion
AXR
AXR
ZYME
ZYME
Q1 26
1.72×
Q4 25
-3.54×
Q3 25
2.03×
Q2 25
2.63×
5.21×
Q1 25
-4.51×
Q4 24
-0.05×
Q3 24
2.63×
Q2 24
2.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons